207 related articles for article (PubMed ID: 22539474)
1. Performance of two commercially available automated immunoassays for the determination of Epstein-Barr virus serological status.
Lupo J; Germi R; Semenova T; Buisson M; Seigneurin JM; Morand P
Clin Vaccine Immunol; 2012 Jun; 19(6):929-34. PubMed ID: 22539474
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Abbott Architect, Siemens Immulite, bioMerieux Vidas, and Euroimmune assays for determination of Epstein-Barr virus serological diagnosis.
Appak O; Ozkaratas MH; Sayiner AA
J Med Virol; 2021 Nov; 93(11):6309-6316. PubMed ID: 34375007
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Architect Epstein-Barr Virus (EBV) viral capsid antigen (VCA) IgG, VCA IgM, and EBV nuclear antigen 1 IgG chemiluminescent immunoassays for detection of EBV antibodies and categorization of EBV infection status using immunofluorescence assays as the reference method.
Corrales I; Giménez E; Navarro D
Clin Vaccine Immunol; 2014 May; 21(5):684-8. PubMed ID: 24623623
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the abbot Architect(™) epstein-barr virus viral capsid antigen IgM, viral capsid antigen IgG and nuclear antigen IgG assays in a pediatric and adult population.
Grandjean Lapierre S; Vallières E; Rabaamad L; Labrecque M; Chartrand C; Renaud C
J Clin Virol; 2016 Aug; 81():1-5. PubMed ID: 27258036
[TBL] [Abstract][Full Text] [Related]
5. Evaluation the Architect EBV VCA IgM, VCA IgG, and EBNA-1 IgG chemiluminescent immunoassays to assess EBV serostatus prior transplantation.
Maylin S; Feghoul L; Salmona M; Herda A; Mercier-Delarue S; Simon F; Legoff J
J Med Virol; 2017 Nov; 89(11):2003-2010. PubMed ID: 28661055
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Abbott Architect
François C; Segard C; Bouvier M; Stefanski M; Pannier C; Zawadzki P; Roussel C; Hecquet D; Duverlie G; Brochot E; Castelain S
Diagn Microbiol Infect Dis; 2018 Feb; 90(2):96-101. PubMed ID: 29198371
[TBL] [Abstract][Full Text] [Related]
7. [Performance of the VIDAS automated immunoassay for the determination of Epstein-Barr virus serological status].
De Ory F; Guisasola ME; Sanz JC; García-Bermejo I
Enferm Infecc Microbiol Clin; 2012 Dec; 30(10):618-20. PubMed ID: 22854635
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Elecsys and Liaison immunoassays to determine Epstein-Barr virus serological status using further diagnostic approaches to clarify discrepant results.
Lupo J; Tsougaev M; Blachier S; Chovelon G; Truffot A; Leroy C; Giai J; Epaulard O; Germi R; Morand P
J Med Virol; 2023 Jan; 95(1):e28166. PubMed ID: 36137986
[TBL] [Abstract][Full Text] [Related]
9. [Atypical profile problem in serological diagnosis of EBV].
Varıcı Balcı FK; Özbek ÖA; Sayıner AA
Mikrobiyol Bul; 2017 Oct; 51(4):378-386. PubMed ID: 29153068
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of four commercial systems for the diagnosis of Epstein-Barr virus primary infections.
de Ory F; Guisasola ME; Sanz JC; García-Bermejo I
Clin Vaccine Immunol; 2011 Mar; 18(3):444-8. PubMed ID: 21191077
[TBL] [Abstract][Full Text] [Related]
11. Analytical performance evaluation of the Elecsys Epstein-Barr virus immunoassay panel.
Schulte-Spechtel U; Berth M; Lauseker-Hao Y; Meyer-Schlinkmann K; Bohnert M; Jochum S; Schuhmann K
Diagn Microbiol Infect Dis; 2021 Nov; 101(3):115443. PubMed ID: 34304105
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of three different assays for the assessment of Epstein Barr Virus immunological status.
Altuglu I; Bozkurt H; Samlioglu P; Zeytinoglu A
New Microbiol; 2007 Oct; 30(4):393-8. PubMed ID: 18080674
[TBL] [Abstract][Full Text] [Related]
13. Serological diagnosis of Epstein-Barr virus infection by novel ELISAs based on recombinant capsid antigens p23 and p18.
Färber I; Hinderer W; Rothe M; Lang D; Sonneborn HH; Wutzler P
J Med Virol; 2001 Apr; 63(4):271-6. PubMed ID: 11241457
[TBL] [Abstract][Full Text] [Related]
14. Measurement of EBV-IgG anti-VCA avidity aids the early and reliable diagnosis of primary EBV infection.
Robertson P; Beynon S; Whybin R; Brennan C; Vollmer-Conna U; Hickie I; Lloyd A
J Med Virol; 2003 Aug; 70(4):617-23. PubMed ID: 12794726
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of primary versus reactivated Epstein-Barr virus infection in patients with VCA IgG-, VCA IgM- and EBNA-1-antibodies and suspected infectious mononucleosis.
Nystad TW; Myrmel H
J Clin Virol; 2007 Apr; 38(4):292-7. PubMed ID: 17336144
[TBL] [Abstract][Full Text] [Related]
16. Evidence-based approach for interpretation of Epstein-Barr virus serological patterns.
Klutts JS; Ford BA; Perez NR; Gronowski AM
J Clin Microbiol; 2009 Oct; 47(10):3204-10. PubMed ID: 19656988
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic Performance and Comparative Evaluation of the Architect, Liaison, and Platelia Epstein-Barr Virus Antibody Assays.
Park Y; Park BG; Ha J; Kim HS
Ann Lab Med; 2018 Sep; 38(5):458-465. PubMed ID: 29797817
[TBL] [Abstract][Full Text] [Related]
18. The impact of serological features in Chinese children with primary or past Epstein-Barr virus infections.
Huang Y; Wei C; Zheng K; Zhao D
Virol J; 2013 Feb; 10():55. PubMed ID: 23406068
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a multiplex flow immunoassay for detection of epstein-barr virus-specific antibodies.
Binnicker MJ; Jespersen DJ; Harring JA; Rollins LO; Beito EM
Clin Vaccine Immunol; 2008 Sep; 15(9):1410-3. PubMed ID: 18632919
[TBL] [Abstract][Full Text] [Related]
20. Comparative evaluation of the new ARCHITECT EBV assays considering different testing algorithms.
Sickinger E; Berth M; Vockel A; Braun HB; Oer M; Buenning C
Diagn Microbiol Infect Dis; 2014 Jul; 79(3):310-6. PubMed ID: 24809858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
